Cancer Cell

Article	Citations
Accelerated approvals: Early-phase success or premature authorization?	2425
Lymphoma accelerates T cell and tissue aging	637
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer	616
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer	571
EGFR-activated myofibroblasts promote metastasis of pancreatic cancer	449
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition	441
TAMing immunity through an unexpected source	394
Hand in hand to successful immunotherapy: CD8+ T cells and M1-like macrophages swap the baton	390
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling	386
The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression	368
Characterization of the generic mutant p53-rescue compounds in a broad range of assays	358
KIT as a therapeutic target in neuroendocrine prostate cancer	324
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients	314
A stratification system for breast cancer based on basoluminal tumor cells and spatial tumor architecture	305
Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancer	298
Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas	297
Long-range cholinergic input promotes glioblastoma progression	287
Spatial profiling technologies illuminate the tumor microenvironment	281
Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations	263
Diet-microbiome interactions in cancer	262
Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses	261
Genetic modeling of ELP1-associated Sonic hedgehog medulloblastoma identifies MDM2 as a selective therapeutic target	261
T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation	258
B cell heterogeneity in cancer comes of age	257
Bacteria in metastatic sites: Unveiling hidden players in cancer progression	256

The aging lung microenvironment awakens melanoma metastases	253
Cancer vaccines	253
T cell dynamism and immune-related adverse events	251
A holistic view of cancer	249
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma	247
High endothelial venules in cancer: Regulation, function, and therapeutic implication	244
Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer	241
A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma	238
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer	238
Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses	233
Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer	218
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors	208
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer	204
Challenges in neoantigen-directed therapeutics	203
Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity	203
Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer	201
Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin	200
Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron	196
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments	196
Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics	193
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer	193
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts	189
Immunosensitivity cuts across mismatch repair status in colorectal cancer	181
Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation	177
Distinct T cell functions enable efficient immunoediting and prevent tumor emergence of developing sarcomas	174
Revisiting TNM staging for EBV-related nasopharyngeal carcinoma	171
The one-two punch: TIM-3 blockade targets immune and tumor cells to knock out pediatric brain tumors	169
Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma	168
Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma	166
A genetic portrait of metastatic seeds in lung adenocarcinoma	165
Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation	163
Gut microbes promote chemoradiotherapy resistance via metabolic cross-feeding	162
Challenges and opportunities for modeling aging and cancer	160
Tumor-directed dysregulation of erythroid progenitors drives immunosuppressive myeloid cells	158
Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma?	157
Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients	156
Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer	155
Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma	154
Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population	154
Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression	153
Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer	150
Hypoxia inducible factor-1α drives cancer resistance to cuproptosis	149
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy	148
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy	148
Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification	148
Integrated single-cell and spatial transcriptomics uncover distinct cellular subtypes involved in neural invasion in pancreatic cancer	147
Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma	143
Recognition of observer effect is required for rigor and reproducibility of preclinical animal studies	142
Single-cell multi-stage spatial evolutional map of esophageal carcinogenesis	138
Tumor-infiltrating lymphocytes: A new hope	136

Response-based molecular subtyping—emergence of the third generation of breast cancer subtypes	134
Midkine as a driver of age-related changes and increase in mammary tumorigenesis	132
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD	131
Integrated proteogenomic characterization of glioblastoma evolution	130
A path to translation: How 3D patient tumor avatars enable next generation precision oncology	130
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells	128
Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers	127
Hepatobiliary tumor organoids for personalized medicine: a multicenter view on establishment, limitations, and future directions	127
Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1	127
Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells	126
Immune determinants of the pre-metastatic niche	123
Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment	122
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness	122
Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring	122
Taxanes directly induce T cell cytotoxic extracellular vesicles to eradicate tumor cells	120
Precise patient stratification in esophageal cancer: Biomarkers for immunochemotherapy	120
A circular RNA in neuroendocrine carcinomas	119
Immunosequencing identifies signatures of T cell responses for early detection of nasopharyngeal carcinoma	118
New horizons at the interface of artificial intelligence and translational cancer research	117
Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance	117
Proteogenomic data and resources for pan-cancer analysis	116
The winner takes it all: Competition drives clonal selection in gliomagenesis	116
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma	115
Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest	112
GDF15 research from bench to bedside	111
Tumors on different wavelengths	110
JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma	110
T cell immune deficiency rather than chromosome instability predisposes patients with short telomere syndromes to squamous cancers	110
Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study	110
Firing up neutrophil anti-tumor immunity with cocktails	109
Distinct spatiotemporal dynamics of CD8+ T cell-derived cytokines in the tumor microenvironment	108
Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma	107
CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma	107
Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer	107
Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial	107
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia	105
Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer	103
Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma	103
Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models	100
KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer	100
Integrated single cell analysis reveals co-evolution of malignant B cells and tumor micro-environment in transformed follicular lymphoma	99
Hidden spark: From cold to hot in BRAF colorectal cancer	99
Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer	98
Spatial transcriptomics reveals tryptophan metabolism restricting maturation of intratumoral tertiary lymphoid structures	97
GD2-CAR T cells in patients with osteosarcoma and neuroblastoma—it’s not only the T cells that matter	96
Lactobacillus reuteri—an old acquaintance takes on a new task in colorectal tumor surveillance	95
An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma	93
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer	91
Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers	90
CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4	90
Plasma cell and cancer stem cell crosstalk in glioblastoma	89
PD-1 blockade is a promising therapeutic addition to neoadjuvant chemoradiation in locally advanced rectal cancer	88
Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers	88
Stromal barriers to the abscopal effect	88
Engineering myeloid cells for cancer immunotherapy	88
Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosis	87
Horizontal mitochondrial transfer in cancer biology: Potential clinical relevance	87
Tumor microbiome links cellular programs and immunity in pancreatic cancer	86
From intestinal metaplasia to gastric cancer: Witnessing the rise of evil over time and space	85
Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy	85
High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer	85
Getting a handle on KRAS inhibitor resistance with hapten-mediated anti-tumor immunity	84
Stromal lipid species dictate melanoma metastasis and tropism	80
Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers	80
Glioblastoma induces the recruitment and differentiation of dendritic-like “hybrid” neutrophils from skull bone marrow	79
Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study	79
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity	79
Squamous cell cancers of the aero-upper digestive tract: A unified perspective on biology, genetics, and therapy	78
The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells	77
Seed or soil: Tracing the immune subsets in metastatic tumors	77
Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site	77
Identification of specific PP2A complexes involved in human cell transformation	76
Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice	76
Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity	75
Architecture sets the path: Breast cancer subtypes differently shape the early brain metastatic niche	75
TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak	74
Infiltrating plasma cells maintain glioblastoma stem cells through IgG-Tumor binding	73
Subclonal immune evasion in non-small cell lung cancer	73
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative	73
Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC	72

When immunotherapy meets surgery in non-small cell lung cancer	72
Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma	72
Increased antibody titers and reduced seronegativity following fourth mRNA COVID-19 vaccination in patients with cancer	71
Revealing de novo pyrimidine synthesis as a key vulnerability in brain tumors	71
Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: A multicenter phase 2 PLATINUM trial	71
Vascular characterization reveals immunomodulatory targets for brain metastases	71
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer	71
A first-in-class EGFR-directed KRAS G12V selective inhibitor	70
Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer	69
Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition	69
Spatiotemporal genomic profiling of intestinal metaplasia reveals clonal dynamics of gastric cancer progression	68
Genomic mapping of metastatic organotropism in lung adenocarcinoma	67
A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma	67
When essential metal elements become culprits—Cuproptosis in focus	67
A Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression	65
Immune memory shapes ovarian cancer recurrence	65
Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma	64
Mutations in IFN-γ signaling genes sensitize tumors to immune checkpoint blockade	64
Sex and cancer immunotherapy: Current understanding and challenges	64
Overcoming melanoma therapy resistance with RAF-MEK and FAK inhibition	64
Bridging the gap: The future of cancer research and clinical oncology in Cancer Cell	63
Carnobacterium maltaromaticum boosts intestinal vitamin D production to suppress colorectal cancer in female mice	63
Understanding and reversing mammary tumor-driven reprogramming of myelopoiesis to reduce metastatic spread	63
Engineered natural killer cells for cancer therapy	62
The liver as a cytokine factory working on mRNA blueprints for cancer immunotherapy	62
A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma	61
Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer	60
The coming era of nudge drugs for cancer	59
Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance	59
IL-6 blockade in cancer patients treated with immune checkpoint blockade: A win-win strategy	59
Immune phenotypic linkage between colorectal cancer and liver metastasis	58
Neutrophil-activating therapy for the treatment of cancer	58
The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells	57
T cell engagers in solid tumors kick the door down	57
Insights into the co-evolution of epithelial cells and fibroblasts in the esophageal tumor microenvironment	57
Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis	57
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity	57
A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis	56
Rethinking relief: Targeting sensory neurons to combat cancer and pain	56
TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors	55
Senescent alveolar macrophages promote early-stage lung tumorigenesis	55
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)	54
Metabolic regulation of Cathepsin B in tumor macrophages drives their pro-metastatic function	54
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts	53
Cooperative CAR targeting to selectively eliminate AML and minimize escape	53
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory	52
A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers	52
Alistipes finegoldii augments the efficacy of immunotherapy against solid tumors	52
Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma	52
Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer	52